Surgery Partners Set to Show Whether Last Year's Hospital Troubles Were Temporary or Structural

Surgery Partners (NASDAQ: SGRY) reports Q1 2026 earnings tomorrow, May 5, before the market open, with analysts bracing for a sharp reversal from recent profitability. The healthcare services provider faces mounting scrutiny after missing estimates badly last quarter and guiding significantly below expectations, raising questions about whether operational headwinds are temporary or structural. With the stock down nearly 20% from its 200-day moving average and analyst sentiment deteriorating, this report will test whether management can restore confidence in the growth trajectory.

Part 1: Earnings Preview

Surgery Partners operates surgical facilities and ancillary services across the United States, partnering with physicians and health systems to deliver outpatient procedures in a cost-effective setting. The company's network spans ambulatory surgery centers and surgical hospitals, positioning it at the intersection of healthcare cost containment and volume growth trends.

Surgery Partners reports Q1 2026 results tomorrow before the open, with the consensus calling for an EPS loss of -$0.17 on estimated revenue of $798.10 million. Last quarter, the company reported EPS of $0.10, missing the $0.27 estimate by 63% in a result that sent shares tumbling. Year-over-year, the outlook has darkened considerably: analysts expect Q1 to swing from a loss of $0.02 in the prior-year quarter to a loss of $0.17 this year, representing -750% growth and signaling deepening profitability pressure.

Three narrative themes dominate the earnings setup:

Margin Compression and Cost Inflation: The company has struggled with labor cost inflation and operational inefficiencies that have squeezed margins despite revenue growth. Investors will scrutinize whether management's cost-reduction initiatives are gaining traction or if structural headwinds persist. The sharp deterioration in EPS guidance—from expectations of $0.35 for full-year 2026 down to just $0.09—reflects analyst concern that margin recovery will take longer than initially anticipated.

Volume Trends and Payer Mix: Surgical case volumes and the mix of procedures (higher-margin elective cases versus lower-margin work) drive profitability in this business. Recent quarters have seen softer volume trends, and analysts are watching for commentary on whether patient demand is stabilizing and whether payer negotiations are yielding favorable rate increases to offset cost pressures.

Full-Year Guidance Reset: After missing both revenue and EBITDA guidance significantly last quarter, management's credibility on forward guidance is under scrutiny. Analysts will be listening for whether the company reaffirms, lowers, or provides more conservative framing around its full-year outlook, particularly given the steep negative growth expected in the first half of 2026.

Ahead of the release, analyst commentary reflects caution. The consensus has shifted materially lower over the past 30 days, with most analysts reconfirming their reduced estimates rather than finding upside. The healthcare providers & services segment has shown positive momentum recently, with peers like Encompass Health and Select Medical beating estimates and trading higher, but Surgery Partners has underperformed, suggesting company-specific challenges rather than sector-wide tailwinds.

Part 2: Historical Earnings Performance

Surgery Partners has delivered a mixed earnings track record over the past four quarters, with two beats and two misses that reveal an inconsistent operational cadence. The company beat estimates by 50% in Q1 2025 (reporting -$0.02 versus -$0.04 expected) and delivered a strong 200% beat in Q2 2025 ($0.12 versus $0.04 expected), suggesting mid-year operational momentum. However, the pattern reversed in the second half: Q3 2025 saw a modest -8.33% miss ($0.11 versus $0.12 expected), followed by a significant -62.96% miss in Q4 2025 ($0.10 versus $0.27 expected) that marked the worst surprise in the trailing year.

The Q4 miss stands out as a clear inflection point—the magnitude of the shortfall and the accompanying guidance reset indicate that the company encountered material headwinds that management had not fully anticipated. The pattern suggests that while Surgery Partners can execute well in certain quarters, it has struggled to sustain consistent performance, particularly as cost pressures have intensified. The company has now missed EPS estimates in two consecutive quarters when considering the Q3 and Q4 results, a concerning trend heading into tomorrow's report.

With analysts expecting another loss of -$0.17 for Q1 2026—far worse than the -$0.02 reported in the prior-year quarter—the bar is set for continued profitability pressure. The question is whether management can stabilize results and provide a credible path back to profitability, or whether the earnings trajectory will continue to deteriorate through the first half of the year.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Surgery Partners typically reports before the market open, meaning Day 0 captures the first reaction session and Day +1 reflects follow-through trading.

Surgery Partners exhibits significant post-earnings volatility, with an average absolute Day 0 move of 6.39% and Day +1 follow-through averaging 4.63%. The stock's reaction pattern is notably asymmetric: negative surprises trigger sharp selloffs, while positive surprises generate more modest rallies. The most dramatic example came in November 2024, when the stock plunged 25.42% on Day 0 and continued lower with a 13.75% decline on Day +1, reflecting a severe earnings miss and guidance cut. Conversely, positive surprises like the May 2024 report produced an 8.48% Day 0 gain but gave back some momentum on Day +1.

The Day 0 range averages 8.36%, indicating that intraday swings can be substantial even when the closing move is more contained. Given the company's recent miss and the steep negative guidance embedded in tomorrow's consensus, investors should prepare for elevated volatility. If Surgery Partners misses again or guides lower, history suggests the stock could face double-digit downside pressure. Conversely, any beat or stabilization in guidance could trigger a relief rally, though the follow-through on Day +1 will depend on the credibility of management's commentary.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 14.67% for the May 15 expiration, significantly higher than the 6.39% average Day 0 move observed historically. This elevated implied volatility of 116.18% suggests options traders are anticipating a larger-than-usual reaction, likely reflecting heightened uncertainty around the company's ability to stabilize margins and guidance after last quarter's significant miss.

Part 3: What Analysts Are Saying

Analysts maintain a cautiously optimistic stance on Surgery Partners, with an average rating of 4.15 (Buy) and a mean price target of $18.68, implying 31.5% upside from the current price of $14.20. The consensus includes 8 Strong Buys, 1 Moderate Buy, 3 Holds, and 1 Strong Sell, reflecting a range of views but a tilt toward bullish sentiment among the majority of the 13 analysts covering the stock.

However, sentiment has deteriorated over the past month. One analyst downgraded from Hold to Strong Sell, and the average recommendation slipped from 4.31 to 4.15, signaling growing caution as the earnings date approaches. The price target range is wide, spanning from a low of $14.00 (barely below the current price) to a high of $25.00, underscoring the divergence in views on the company's recovery timeline. The mean target of $18.68 suggests that even after recent underperformance, analysts see meaningful upside if management can execute on cost controls and volume stabilization.

The deterioration in sentiment reflects the sharp downward revisions to earnings estimates following last quarter's miss. Analysts have cut full-year 2026 EPS expectations from $0.35 to $0.09, a -74.29% reduction, indicating that the Street is now modeling a much slower path to profitability. The silver lining is that full-year 2027 estimates call for EPS of $0.24, implying 166.67% growth and suggesting analysts believe the current weakness is cyclical rather than permanent. Tomorrow's report and guidance will be critical in determining whether that optimism is justified or if further downgrades are ahead.

Part 4: Technical Picture

Surgery Partners enters earnings with a deteriorating technical picture, as the Barchart Technical Opinion has shifted from a 100% Sell signal one month ago to a 56% Sell last week, and now stands at a 40% Sell today. While the signal has moderated slightly in recent days, the overall trend remains negative, reflecting persistent selling pressure and a lack of sustained buying conviction.

Timeframe Analysis:

• Short-term (Hold): Neutral signal suggests the stock is consolidating near current levels with no clear directional bias heading into earnings
• Medium-term (50% Sell): Moderate sell signal indicates weakness in the intermediate timeframe, consistent with the stock's underperformance relative to moving averages
• Long-term (100% Sell): Strong sell signal reflects a broken longer-term uptrend and sustained downside pressure over the past several months

The trend is characterized by Average strength and the Weakest direction, indicating that while the selling pressure is not extreme, the directional momentum is firmly negative and offers little technical support heading into the earnings release.

The stock is trading at $14.20, above the 5-day ($14.14), 20-day ($13.79), and 50-day ($13.40) moving averages, but below the 10-day ($14.35), 100-day ($14.42), and 200-day ($17.62) moving averages. This mixed positioning suggests short-term stabilization after recent weakness, but the stock remains well below its longer-term trend lines, with the 200-day average acting as significant overhead resistance nearly 24% above current levels.

Key resistance sits at the 100-day moving average of $14.42, just above the current price, while support is found near the 50-day average at $13.40. The stock's failure to reclaim the 200-day moving average reflects the severity of the selloff following last quarter's miss. With the technical setup offering little cushion and the options market pricing in a 14.67% move, the risk/reward heading into earnings tilts cautionary. A beat and credible guidance could spark a relief rally toward the $16–$17 range, but another miss risks a retest of the $12–$13 support zone established earlier this year.